Endocrinology Strategic Roundup exploring Key Strategic Developments and Competitive Shifts
Coverage Period: July 21 – August 17, 2026
Introduction
The defining story of this reporting period was the shift in diabetes competition from glucose-lowering efficacy alone toward reducing treatment burden across the patient journey. Once-weekly insulin, new biosimilar entry, more scalable injectable delivery platforms, AI-enabled glucose monitoring and standardized support at diagnosis all addressed different points of friction in diabetes care. The strategic significance is that convenience, access, usability and integration into routine care are becoming more important alongside clinical performance. At the same time, preclinical cell-replacement research continues to test whether future therapies could move beyond chronic management toward durable restoration of insulin production.
Executive Summary
- Lower treatment burden is becoming a stronger competitive lever in diabetes. NICE’s recommendation of once-weekly Onswik and European authorizations involving Stevanato Group’s Alina pen platform show how dosing frequency and delivery design can influence patient convenience, caregiver requirements and commercialization.
- Insulin competition is widening through biosimilars and distributed development models. FDA approval of Garzulys adds another rapid-acting insulin option while showing how international manufacturing, clinical, regulatory and commercialization partners can combine capabilities to compete in complex biologics.
- Glucose monitoring is moving upstream toward earlier intervention. Dexcom’s participation in the FDA TEMPO pilot will test whether glucose biosensing, contextual health data and AI-supported insights can support screening, prevention and population-level metabolic management.
- Health systems are placing more emphasis on the point of diagnosis. Wales’ standardized Type 2 diabetes resources reflect recognition that early education and consistent support may influence long-term engagement and complication prevention.
- Cell-based therapy remains a longer-term disruptive possibility. Rice University research using localized IL-10 to protect implanted insulin-producing cells highlights continued progress toward reducing the need for systemic immunosuppression, although the approach remains preclinical.
Watch the video summary
Strategic Perspective on the latest Endocrinology Trends
Once-Weekly Insulin and Injection Platforms Raise the Value of Convenience in Type 2 Diabetes
This reporting period reinforced treatment convenience as a more visible competitive factor in insulin and injectable diabetes care.
NICE recommended Eli Lilly’s once-weekly insulin Onswik for NHS use, subject to UK marketing authorization. Data from the QWINT program showed non-inferior A1C reduction compared with daily insulin regimens, while weekly dosing could substantially reduce injection frequency. NICE also highlighted potential value for people who require help administering insulin because of impaired vision, frailty, limited dexterity or other practical barriers.
The market implication is that differentiation may increasingly depend on what happens around the clinical endpoint. When glycemic control is comparable, fewer injections could improve treatment acceptability, reduce caregiver involvement and make insulin initiation or continuation easier for selected patients.
Drug-delivery technology supports the same direction of travel. European marketing authorizations for liraglutide combination products using Stevanato Group’s Alina variable-dose pen show how injector design and manufacturing readiness are becoming part of competitive strategy as GLP-1 and other self-administered injectable markets expand.
Key Uncertainty: The commercial value of greater convenience remains dependent on reimbursement, pricing, prescribing behavior and real-world persistence. It is not yet clear how much patients and health systems will value reduced dosing frequency relative to established daily options.
Insulin Biosimilars Expand Diabetes Competition Through Global Partnership Models
FDA approval of Garzulys, a biosimilar to NovoLog, broadens competition in the U.S. rapid-acting insulin market while highlighting a business model that may matter beyond a single product.
The program distributes key functions across several organizations: drug substance and drug product development, clinical execution, regulatory work, supply-chain responsibilities and U.S. commercialization. Meitheal holds exclusive U.S. commercialization rights, while the broader collaboration also includes two additional insulin biosimilar candidates.
This matters because entry into insulin no longer requires every capability to sit inside one vertically integrated company. Specialized partners can combine development, manufacturing, regulatory and commercial infrastructure to build biologics portfolios across markets. That model may lower some organizational barriers to participation in complex, mature therapeutic categories.
For incumbent manufacturers, additional approved biosimilars could add pricing and contracting pressure over time. For smaller or mid-sized biopharma companies, the Garzulys pathway illustrates how partnerships can support expansion from conventional generics into biologics.
Key Uncertainty: Approval does not establish commercial traction. Pricing, formulary placement, payer contracting, supply reliability and physician adoption will determine whether Garzulys materially changes competitive dynamics.
Continuous Glucose Monitoring Moves Toward Prediabetes and Earlier Metabolic Intervention
Dexcom’s selection as the first participant in the FDA’s TEMPO Digital Health Devices Pilot Program points to a potentially broader role for continuous glucose monitoring beyond established diabetes management.
The planned program combines data from Dexcom G7 and Stelo with information on nutrition, physical activity, sleep and stress. It is intended to generate personalized insights for users and clinicians while supporting real-world evidence generation around prediabetes, Type 2 diabetes and earlier intervention.
The competitive signal is a move upstream in the care pathway. If glucose biosensing can demonstrate value in identifying risk, supporting behavior change or guiding early clinical intervention, continuous glucose monitoring companies could participate in a substantially wider metabolic-health market. Their competitive position would depend not only on sensor performance but also on software, analytics, clinical workflows and evidence supporting broader use.
Wales’ national Point of Diagnosis resources reflect a related shift in care delivery. Standardized patient and clinician materials, combined with a redesigned diabetes digital hub, are intended to reduce variation in support immediately after a Type 2 diabetes diagnosis. That reinforces the view that earlier engagement may become an increasingly important part of diabetes management strategy.
Key Uncertainty: Broader use of glucose data will require evidence that earlier monitoring and digital intervention improve meaningful outcomes. Reimbursement, clinical workflow integration and the appropriate role of CGM in people without established diabetes remain unresolved.
Cell-Based Type 1 Diabetes Therapies Target the Immunosuppression Barrier
While near-term market activity focused on making chronic diabetes management easier, preclinical research continues to pursue a more disruptive goal: restoring endogenous insulin production.
Rice University researchers tested a localized IL-10 strategy designed to protect implanted insulin-producing cells from immune rejection. In diabetic mice, protected cells maintained glucose control for more than 100 days, while testing in nonhuman primates showed continued IL-10 production without reported harmful systemic effects.
The strategic importance lies in the immune-protection problem. Cell replacement has the potential to change Type 1 diabetes treatment fundamentally, but graft rejection and the risks associated with systemic immunosuppression remain major barriers. A localized approach that reduces fibrosis and protects implanted cells could improve the feasibility of future implantable therapies.
The broader market implication is that long-term competition in Type 1 diabetes may eventually extend beyond insulin delivery and glucose monitoring toward therapies designed to restore physiological glucose regulation.
Key Uncertainty: The findings remain preclinical. Human safety, durability, scalability, manufacturing feasibility and sustained glycemic efficacy have not been established, and clinical translation remains uncertain.
Next Endocrinology Strategic Watchpoints
- Regulatory progress for once-weekly insulin, including UK authorization following NICE’s recommendation and additional decisions in Europe and the U.S.
- Commercial uptake of Garzulys, particularly pricing, formulary access and payer positioning relative to established rapid-acting insulins.
- Evidence from the FDA TEMPO pilot on whether glucose biosensing and AI-supported programs can improve screening, early intervention or broader cardiometabolic outcomes.
- Implementation of Wales’ national Type 2 diabetes diagnosis resources, including whether standardized support improves engagement or reduces variation in care.
- Translation of localized immune-protection strategies into clinical development, especially evidence on safety, graft durability and avoidance of systemic immunosuppression.
Endocrinology Strategic Roundup: Key Takeaway
The most important strategic implication from this period is that reducing friction in diabetes care is becoming a competitive objective in its own right. Weekly insulin addresses dosing burden, biosimilars expand access and competitive choice, digital glucose platforms aim to move intervention earlier, and standardized diagnosis support targets the first stages of chronic disease management. These developments do not displace efficacy as the foundation of treatment, but they indicate that future competitive advantage may depend increasingly on how effectively a therapy or technology fits into real-world care.
About LucidQuest
LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.
Contact us at: info@lqventures.com